The purpose of this registry study was to provide an overview of trends and results of liver transplantation (LT) in Europe from 1968 to 2016. These data on LT were collected prospectively from 169 centers from 32 countries, in the European Liver Transplant Registry (ELTR) beginning in 1968. This overview provides epidemiological data, as well as information on evolution of techniques, and outcomes in LT in Europe over more than five decades; something that cannot be obtained from only a single center experience. The order of the co-authors from 2 to 40 was determined according to the decreasing number of liver transplants recorded in the ELTR. The list with all the centers is available at the following link: http://www.eltr.org/spip.php?page=ce nters-tous
Introduction

Background of the European Liver Transplant Registry
Created in 1986, the ELTR has collected the data of liver transplantation (LT) from 175 centers all over Europe since 1968. The registered data represents more than 95% of the overall European data compared with the published official figures [1] .
Questionnaire
The ELTR questionnaire includes data on indications for LT, donors and recipients characteristics, technical aspects of LT (with reduced, split, domino, live and nonheart beating donors), initial and current regimen of immunosuppression, patient outcomes, and cause of death or graft failure. The ELTR has developed an online application (Electronic Data Capture -EDC) for collecting data. A Web-based module was developed to allow for real-time data capture. Software, questionnaires, validation routines, and statistics are located on a central server, which can be accessed by the participating centers with a standard internet browser [2] .
To avoid an overlap in case of multiple diagnoses, the ELTR has two variables to report the diagnosis (Disease1 & Disease2) and an open field for specification in case a diagnosis is not available in the official pull-down menu, or in case there are more than two combined diagnoses. A standard procedure was stated accordingly for the data entry and their analysis in each condition.
Quality control of the data
The data-entry process is dynamically controlled. The data are subjected to routine checks for completeness, consistency, and range. Comprehensive logical intraand inter-updates are performed. In addition, a control of the good adequacy between ELTR questionnaire and patient charts is performed by randomly conducted audit visits to the centers. The ELTR audit visits have been continuously conducted since 1998 with, initially 10 randomly selected centers per year up to the year 1999, and five centers per year since 2000. Two auditors perform the visit with the condition that both are not from the visited country. Ten percent of center's files, with a minimum of 20 and a maximum of 50, are analyzed to check data for completeness and consistency. The audit visits serve also to train staff members, and to introduce amendments in the procedure. It is also the opportunity to meet with the staff of centers, something that is valuable for creating a team spirit. The ELTR is considered as the pioneer of external audit visits of a scientific registry. The audit report is sent confidentially to the head of the center with all the discrepancies noted, and the recommendations necessary to improve the data entry included. The results of all center audits are presented during the ELTR biennial workshops, where all the contributing centers are invited. A recent analysis of the ELTR audit data (38 centers from 16 countries, 57 575 variables from 1458 patient files, from 2010 to 2016) showed that the overall rates of completeness and consistency were 94.5% and 97.3% respectively. Audit visits are an indicator of the quality of data, and represent one of the pillars of the ELTR. These results have indicated that ELTR data are reliable, and the scientific results of ELTR can be considered credible and representative of LT in Europe [3] [4] [5] [6] .
Partnership with organ sharing organizations (OSOs)
The ELTR has established agreements with the main national and international OSOs: United Kingdom Transplant Service Support Authority -UK NHS Blood and Transplant, Spanish Organizacion Nacional de Trasplantes -ONT, Scandinavian Scandiatransplant -SKT, Dutch Transplant Foundation -NTS, Eurotransplant Foundation -ET, French Agence de la Biom edecine -ABM to exchange data collected from European Centers and to cross check common data between OSO and ELTR.
Source of the data
There are two sources of ELTR data; 72% of data (63% of centers) are shared with the OSOs and 28% of data (37% of centers) are directly entered into the ELTR EDC platform. Some variables were added to the questionnaire, and some definitions have changed since the registry was created in 1986. To adapt the ELTR to these evolutions, an experts committee was appointed to oversee the standardization of the questionnaire. The European Liver and Intestine Transplant Association (ELITA) board and the OSOs share this concern and are also attentive to all the evolutions.
Previous ELTR achievements
The ELTR regularly carries out thematic studies related to the different fields of LT. These studies minimize the potential biases, by assessing interactions between confounding factors and identification of independent predictors among all the ELTR variables that can have an impact on the outcome. A sample of these studies is cited in the references of the manuscript. With reports concerning LT for specific hepatic diseases [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] , analysis of the impact of the type of preservation solution [25] , and of the immunosuppressive regimen on the patient outcome [26] , ELTR has helped develop risk models for mortality following liver-transplantation [27, 28] . Owing to the large cohort of patients, the exhaustiveness, and quality of the data, and the long follow-up provided by the ELTR, the results are really representative of LT in Europe.
The objective of this paper is to report these results and their evolution in adults as well as in pediatric recipients.
Patients and methods
The whole data since 1968 was considered initially to show the evolution of results of LT in Europe since its initial development. The rest of analysis was then undertaken considering two different periods: (i) January 1988 to December 2016 (147 161 LT -127 851 patients) [January 1988 was chosen corresponding to the introduction and widespread use of cyclosporinebased immunosuppression, and standardization of the surgical procedure], (ii) the last 15-year period data from January 2002 to December 2016 (99 562 LT -91 183 patients) to give a more recent evaluation of LT results in Europe.
Data were generally analyzed as a whole (except for some variables), without making a distinction between adult and pediatric population, the latter representing 10% of LT in Europe. Kaplan-Meier analysis was used to estimate graft and patient survival stratified by conditions group; statistical analyzes were performed using the log-rank test (P < 0.05 as significant) with SAS â Version 9.1.3 Entreprise Guide version 5.1 (Copyright© 2012 by SAS Institute Inc., Cary, NC, USA). The dynamics of data control was continued during the statistical analyzes. Calculation of survival rates was determined by the actuarial method.
Results
From May 1968 to December 2016, the ELTR has collected data concerning 146 782 LTs in 132 466 patients, from 169 Centers, and 32 countries (Fig. 1) . These data give a comprehensive overview of the status and evolution of LT in Europe. Both the number of transplant centers and the annual number of LT's performed in Europe have gradually increased since the ELTR was created (Fig. 2) . However, after an exponential increase from the eighties, a plateau seems to have been reached in recent years with about 7300 LTs performed all over Europe annually.
Main indications of LT in Europe
The main indications for LT in Europe with the corresponding graft and patient survival rates at 1, 5, 10, and 15 years in the whole ELTR population and in the last 15 years cohort are listed in Table 1 . Twenty-year survival is provided for the whole ELTR population. Cirrhosis was the most frequent indication (50%), mainly related to either viral infection (22% with 12% of hepatitis C virus (HCV) infection and 5% of hepatitis B virus (HBV) infection), or to alcohol abuse (19%). Combined viral and alcoholic (ALD) cirrhosis represented 2.4% of indications, with 2% of HCV-ALD. Cirrhosis is followed by three major indications: primary liver tumors (17%, predominantly hepatocellular carcinoma -HCC, 15%), cholestatic liver diseases (10%), and acute hepatic failure (9.1%, 2% of which are virus-related, 2.4% drug related, 0.3% toxic nondrug related and 4.4% of unknown cause). The most common etiologies of the underlying cirrhosis in HCC patients were HCV (43%), ethanol abuse (27%), and HBV (16%). Cholestatic diseases included primary biliary cirrhosis (5%) and primary sclerosing cholangitis (5%). Biliary atresia (4%) Figure 3 Evolution of indication according to three eras.
represented the major congenital biliary disease. Metabolic diseases represented 6% of all the indications with three major indications being familial amyloidotic polyneuropathy, Wilson disease, and alpha-1-antitrypsin deficiency (1% each). Budd-Chiari and benign liver tumors (mainly polycystic disease) represented only 1% of the indications for LT. Secondary liver tumors (mainly neuroendocrine) represented 0.5% of LT's.
Indications for Pediatric liver transplants
The proportions of the main indications for LT are differently distributed according to the age of recipients. While biliary atresia and metabolic diseases were the major indications in pediatric patients (≤18 years), cirrhosis with end stage liver disease, and cancer were the major indications in adults. An exponential increase in the proportion of cancer cases was noted with recipient age. Acute liver failure (ALF) mostly of unknown cause was frequent in young patients, with the highest incidence at 18-24 years.
Evolution of indications
The percentage of main indications has significantly changed with time (Fig. 3) . Whereas cancers represented 12% of indications before 1997, their incidence has doubled in the last decade to represent currently more than 24%. Metabolic diseases and primary sclerosing cholangitis have slightly increased during the last decade. Conversely, while comparing the last decade with the previous one, we found that the proportion of cirrhosis alone, ALF and primary biliary cholangitis decreased. The decrease in cirrhosis is mainly because of the decrease in HCV cirrhosis, and the reduction in ALF cases is mainly because of the decline of ALF of unknown origin.
Survival according to the indication for LT
When all indications were considered, during the entire study period, patient survival rates were 83% at 1 year, 71% at 5 years, 61% at 10 years, 51% at 15 years, and 41% at 20 years. After an improvement between 1985 and 2000, the survival of patients appears to be relatively steady since 2000 (Fig. 4) . The improvement in survival was seen in patients transplanted for all the three main indications; cirrhosis (Fig. 5a ), fulminant hepatitis (Fig. 5c ) but was particularly regular in LT for cancers (Fig. 5c) . The 5-year patient survival rate was significantly better for cirrhosis (71%) than for primary liver tumors (64%, P < 0.001) and acute hepatic failure (65%, P < 0.001). HBV and HCV co-infection had a better 5-year survival (80%) compared with mono-infection with HCV (64%) or HBV (74%). The better 5-year survival rates obtained in metabolic diseases (79%), cholestatic disease (79%), and congenital biliary disease (85%), are partly explained by the high percentage of children in these groups. The survival rates in adults and children were, respectively, 76% and 85% for metabolic diseases, 79% and 86% for cholestatic disease, and 82% and 85% for congenital biliary disease. The details of survival rates at 1, 5 and 10, 15 and 20 years according to the primary indication are listed in Table 1 .
Although the 5-year survival improved in the 15 recent years for all the indications, the most important gain in survival was observed in LT for primary liver tumors (67%), liver metastases (61%), and acute liver failure (69%).
Since the adoption of the transplantation Model for End-stage Liver Disease (MELD) score in the majority of European countries in 2006-2007, the proportion of patients with a high MELD score (>30) at transplant has almost doubled. However, the survival of these patients is less optimal, especially for those with a MELD score at transplant higher than 40 (Fig. 6) .
Survival according to donor and recipient characteristics
Donor characteristics
The majority of donors were male (57%). Fifty-eight percent were younger than 50 years, whereas 23% were older than 60 years. A gradual increase in the percentage of livers coming from septuagenarian donors was in relation to the increasing gap between a growing waiting list and a relatively stable donor pool (Fig. 7) . Graft survival when organs were procured from donors younger than 55 years was significantly better than that with organs from donors older than 65 years (67% vs. 60% at 5 years, P < 0.0001) (Fig. 8) . However, attention should be paid to the donor to recipient matching to interpret these results, older donor livers being more frequently transplanted to older recipients.
Recipient age
In addition to the better 5-year survival of pediatric versus adult LT recipients (90% vs. 81%, P < 0.0001), an influence of age was noted for adult recipients. Survival rates were 75% for adults aged 18-45 years, 71% for 46-60 years, 65% for 60-70 years, and 60% for septuagenarians. However, average age of transplanted recipients has increased steadily during the last decade, and patients older than 60 years, who represented <5% in the 1980s, currently represent more than 30% of transplant recipients (Fig. 9) . Older grafts are more frequently transplanted to older recipients. Septuagenarian recipients received 43% grafts older than 60-years and only 12% of grafts younger than 30-years, explaining at least in part, the difference in survival between recipient age groups (Fig. 10) . Importantly, LT offered a 10-year survival up to 40% in septuagenarians.
Blood group compatible and incompatible transplants
In elective conditions, 93% of LTs were isogroup, and 6.5% were compatible, whereas in emergency, 3% of LT were incompatible. In both elective and emergency conditions, isogroup LTs had a better 5-year survival compared with compatible or incompatible LTs (66% vs. 62% vs. 57%, P < 0.0001) and (56% vs. 53% vs. 28%, P = 0.001) respectively. However, the use of these incompatible grafts in emergency indications allows a 38% survival rate at 1 year in patients otherwise expected to have a fatal outcome. 
Survival according to surgical technique
Auxiliary grafts represented 0.5% of overall LTs with a similar graft survival as compared with nonauxiliary grafts in urgent (5-year survival rates: 57% vs. 56%), and elective (66% vs. 69%) indications. The shorter the ischemia time; the better was the graft survival. Five-year survival was 70% for ischemia time <6 h, 67% for 6-12 h, 63% for 12-15 h, and 58% for >15 h. The use of static graft preservation solutions evolved during three distinct periods: period 1 before 1990 with the main use of Collins solution; period 2 between 1990 and 2000 with the almost exclusive use of UW (University of Wisconsin); period 3 after 2000 with an increasing use of new solutions with different characteristics such as HTK, Celsior, IGL 1 or SCOT (Fig. 11) . Overall graft survival at 5 years for the main solutions was 74% for Celsior and IGL 1, 72% for UW and 69% for HTK (Fig. 12) . If only partial livers were considered, survival was 83% for IGL 1, 79% for Celsior, 77% for UW, and 71% for HTK.
Alternative procedures to LT using full size livers from donors after brain death (DBD) have been increasingly used in recent years. While representing <10% before 2000 they concerned more than 20% of overall LT procedures after 2000 and 75% in pediatrics. A differentiation between adult and pediatric patients is necessary; because alternative techniques are used differently in each population and the patient's outcome may differ.
Adult population
Before 1994, alternative procedures concerned mainly reduced and split livers. Domino grafts were introduced in 1994 and living donation in 1996. Donation after cardiac death (DCD) was introduced in 2001 and since then, has gradually increased to represent currently almost 40% of the alternative procedures in adults. Consequently, the proportion of split, living, reduced, and domino grafts has decreased. The latter two modalities are really associated with the more significant decrease (Fig. 13a) . Ten-year graft survivals for each type of graft are summarized in Fig. 13b . Survival at 5 years was similar between DBD full size grafts, split liver, domino, and DCD (66% to 67%), but higher than that of reduced grafts and living donors (63% in both). 
Pediatric population
Before 1988, alternative procedures concerned mainly reduced livers. Split livers were introduced in 1988 and living donation in 1991 and since their introduction both have gradually increased to represent currently more than 90% of the alternative procedures in children (Fig. 14a) . Ten-year graft survivals for each type of graft are summarized in Fig. 14b . Survival at 5 years was similar between DCD and living donors (80% and 78%, respectively), but higher than that of DBD full size grafts, split liver, and reduced grafts (74%, 71%, and 65% respectively). Domino transplant is rarely used in pediatric patients.
Mortality after LT
While 1 year patient survival was 81% between 1995 and 1999, it has dramatically improved to reach 86% after 2010 (Fig. 4) . The critical period for post-LT outcome is represented by the first year: 46% of deaths and 67% of re-LT occur within the first year after LT (Fig. 15) . In 44% of cases, re-LT is indicated in the month after primary LT, and more than a half (59%) of patients who die, do so within the 6 months after LT.
Data represented in Fig. 16 correspond to the distribution of main causes of death according to the time of their incidence. Main causes of death in the 28 637 patients who died after primary LT or Re-LT were differently distributed. Whereas death from primary graft nonfunction or dysfunction, infections, and technical (biliary or vascular) complications were more frequent within the first 6 months post-LT, tumor or nontumor recurrence and tumor de novo were more frequent after the first month. Interestingly, the proportion of tumor and nontumor recurrences as a cause of death is decreasing during the last years. 
Re-transplantation
Five-year graft survival rates following a second and a third LTs were 48% and 42%, respectively, significantly lower than those for primary LT (66% -P < 0.0001) (Fig. 17) .
Re-LT was indicated in 8482 cases mainly for primary nonfunction, technical complications (biliary or vascular), and rejection within the first month post-LT. Tumor or nontumor recurrences and de novo tumor were more frequent after the first month (Fig. 18) . Late re-LT, more than 1 month after the first LT, has a significantly better graft survival than early re-LT performed within the month after the first LT (50% vs. 45% at 5 years, P < 0.0001) (Fig. 19) . Re-LT which is mostly used in young patients (Fig. 3a) has declined during the last decade (Fig. 3b) . Interestingly, tumor causes and nontumor recurrence are decreasing during the last years, whereas technical complications, primary graft nonfunction or dysfunction and infection are increasing.
Waiting time
When more than 90% of candidates waited <3 months in the 1980s, they represented 70% in the 1990s and slightly more than a half since 2000. This evolution is likely because of three main reasons: the increase in the number of candidates for transplantation following the advent of more and more effective immunosuppressive treatments, the scarcity of grafts and the use of the MELD which gives priority to the sickest candidates. The 5-year survival of patients who have spent <3 months on the waiting list, certainly because they were more severe, was 70%, 5% lower than that of all the other groups of waiting times in the list (P < 0.0001).
Discussion
The ELTR data provide a descriptive overview of the overall situation of LT in Europe. There is of course heterogeneity in the policies in the 29 contributing countries. This manuscript summarizes the results as a whole, and represents a kind of freeze-frame rather than a generalized statement for Europe. At the same time, the ELTR remains the unique entity capable of providing such statistics, capable of giving a global snapshot of the European experience, and helping to identify important trends that may guide further practice.
Liver transplantation has become the best, if not the only effective treatment for severe irreversible liver disease. More than 7000 LTs are performed annually in Europe, and the results look satisfactory at 5 years (71% survival) with still a room for improvement at long-term (61% at 10 years and 41% at 20 years). The demand far exceeds the availability of organs for transplantation. It is therefore essential to continue to promote organ donation in Europe in order to avoid mortality on the waiting list, and a "drastic" selection of candidates. By allowing the transplant of the sickest candidates first, the MELD score has dramatically decreased the risk of death on the waiting list. However, the post-LT survival of high MELD score patients is less optimal, mostly for those with MELD score at transplant higher than 40. It also appears essential to continue to improve the perioperative management of LT at all levels, along with a better prevention of long-term complications. The data provided by the ELTR are a basis to target the timing, and fields to improve the results.
The main indication for LT is cirrhosis with end stage liver disease. However, its proportion is decreasing continuously as compared with HCC. Fulminant hepatitis of unknown cause is also declining. Such relative diminution of cirrhosis is mainly related to the accelerated decline in HCV indications as a result of effective direct-acting antiviral drugs [17] . Thus, hundreds of liver grafts every year are becoming available for indications other than HCV. Even though NASH related cirrhosis is still less frequent in Europe compared with the US, it is anticipated to become the leading indication for LT within the next decade. In terms of results, all the indications have shown an improvement of survival especially HCC, mainly because of a better selection of patients, and the increasing effectiveness of down-staging techniques [18] . The ELTR cohort of patients has also established that some rare malignant tumors like hepatic hemangiosarcoma should be considered absolute contraindications for LT [19] , while others like hereditary hemorrhagic telangiectasia [8] or hepatic epithelioid hemangio-endothelioma represent a good indication even in the presence of limited extrahepatic disease [12, 24] .
The average age of transplanted recipients has increased steadily during the last decade and a third of patients transplanted nowadays are >60 years. Noteworthy, LT can offer a 10 additional year benefit to 40% of septuagenarians. Also, an increasing number of transplanted liver grafts are coming from older donors with in most cases, the application of the old-to-old rule concerning the donor to recipient matching.
Alternatives to the conventional DBD full size graft are increasingly used in Europe. Split liver and living donation are increasingly used both in adult and pediatric LT, and DCD grafts are mostly used in adults with quite good survival results. Domino and reduced livers seem to be gradually disappearing. Optimization of donor management and organ preservation, offers the most realistic way to improve both the quality and pool of current organs. While only UW solution was used before 2000, an increasing number of new solutions are available today; the choice in preservation solution may have an independent impact on graft survival [25] .
Also, while the introduction of cyclosporine and more recently Tacrolimus optimized immunosuppressive protocols, there is still room for improvement as recently shown by the use of prolonged release tacrolimus [26] .
As a cause of graft loss, technical complications, primary graft nonfunction or dysfunction and infection are increasing, relatively. This could be related to the increasing use of marginal grafts coming from expanded donor criteria. Conversely, de novo tumor and nontumor recurrence as cause of graft loss or mortality are decreasing during the last years. There are some limitations to our study. Data quality, reliability, and representativeness is an everyday concern for the ELTR since its creation in 1986. With this constantly in mind, the ELTR has implemented several procedures and adapted them all along the years to control the quality of data, from collection, to statistical analysis. However, biases may persist as for all observational studies; therefore, the interpretation of these descriptive data must be done with caution. Lost-to-follow-up (LTFU) patients are a real problem in the reported outcome. It is mainly related to the increasing number of transplanted patients who move to another place within a country or outside the country. More than 72% of ELTR data are shared with official OSOs who have setup a drastic tracking procedure to minimize the rate of LTFU. The remaining 28% who enter the data directly in our platform are regularly invited to consult the dynamically updated list of queries to solve all discrepancies and to report a recent patient follow-up.
By the prospective evaluation of almost all patients transplanted in Europe since the last fifty years, the ELTR provides valuable data concerning the evolution of LT, the dynamic changes in indications, in donor and recipients profile, as well as in preservation, technical aspects and post-transplant management. These data can help refine the indications for transplant in rare diseases, and establish new guidelines, while targeting the real fields which need improvement in order to optimize the results of LT.
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